# QUILT-505 (NCT06239220)

> PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

No report yet. It can be ordered.

- Drugs tested: PD-L1 t-haNK plus NAI plus cetuximab
- Indication: immunotherapy-treated recurrent metastatic HNSCC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06239220
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions: PD-L1 t-haNK; Cetuximab; NAI
- Enrollment: 25
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on QUILT-505 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=quilt-505-nct06239220
